炎症性肠病患者接种 SARS-CoV-2 疫苗后的不良事件和血清学反应。
Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease.
机构信息
Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Alberta Precision Laboratories, Public Health Laboratory, Alberta, Canada.
出版信息
Am J Gastroenterol. 2023 Sep 1;118(9):1693-1697. doi: 10.14309/ajg.0000000000002337. Epub 2023 Jun 22.
INTRODUCTION
We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare.
METHODS
Individuals with IBD were interviewed for adverse events to SARS-CoV-2 vaccine. Multivariable linear regression assessed the association between antibody titers and ISR.
RESULTS
Severe adverse events occurred in 0.03%. ISR were significantly associated with antibody levels after the fourth dose (geometric mean ratio = 2.56; 95% confidence interval 1.18-5.57). No cases of IBD flare occurred.
DISCUSSION
SARS-CoV-2 vaccines are safe for those with IBD. ISR after the fourth dose may indicate increased antibodies.
简介
我们确定了患有炎症性肠病 (IBD) 的个体在接种 4 剂严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疫苗后的不良事件、抗体与注射部位反应 (ISR) 之间的关联，以及 IBD 发作的风险。
方法
对患有 IBD 的个体进行 SARS-CoV-2 疫苗不良事件的访谈。多变量线性回归评估了抗体滴度与 ISR 之间的关联。
结果
严重不良事件发生率为 0.03%。ISR 与第四剂后抗体水平显著相关（几何平均比=2.56；95%置信区间为 1.18-5.57）。未发生 IBD 发作。
讨论
SARS-CoV-2 疫苗对 IBD 患者是安全的。第四剂后 ISR 可能表明抗体增加。
Zotero 插件